TDI-10229

TDI-10229 is a potent, selective, and orally bioavailable small molecule inhibitor of soluble adenylyl cyclase (sAC, encoded by ADCY10). Developed through structure-based drug design by the Therapeutics Discovery Institute in collaboration with researchers at Weill Cornell Medicine, it is a second-generation sAC inhibitor with improved potency and pharmacokinetics compared to earlier compounds like LRE1. TDI-10229 is primarily being investigated as a first-in-class, on-demand, non-hormonal male contraceptive due to its ability to acutely inhibit sperm motility and maturation. Additionally, it has been utilized as a pharmacological tool to study the regulation of intraocular pressure (IOP), where sAC inhibition is associated with elevated IOP, suggesting potential therapeutic relevance in treating ocular hypotony or understanding the pathophysiology of glaucoma.